These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 17497733

  • 21. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate.
    Samy R, Faustino PJ, Adams W, Yu L, Khan MA, Yang Y.
    J Pharm Biomed Anal; 2010 Apr 06; 51(5):1108-12. PubMed ID: 20031362
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.
    Yaguchi A, Akahane K, Tsuchioka K, Yonekubo S, Yamamoto S, Tamai Y, Tatemichi S, Takeda H.
    BMC Nephrol; 2019 Dec 12; 20(1):465. PubMed ID: 31830936
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Phosphate binder up to date].
    Shigematsu T, Sakaguchi T, Orita H.
    Clin Calcium; 2007 May 12; 17(5):772-8. PubMed ID: 17471009
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effects of efficient phosphate binding on bone in chronic renal failure rats.
    Behets GJ, Gritters M, Dams G, De Broe ME, D'Haese PC.
    Ren Fail; 2005 May 12; 27(4):475-84. PubMed ID: 16060138
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Kinetic and thermodynamic evaluation of phosphate ions binding onto sevelamer hydrochloride.
    Elsiddig R, Hughes H, Owens E, O' Reilly NJ, O'Grady D, McLoughlin P.
    Int J Pharm; 2014 Oct 20; 474(1-2):25-32. PubMed ID: 25102115
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. High Phosphate-Binding Capacity of Oxylanthanum Carbonate with a Low Medication Volume: Comparison with Commercially Available Phosphate Binders.
    Sprague SM, Reddy G, Jermasek D, Gupta P.
    Am J Nephrol; 2023 Oct 20; 54(5-6):219-223. PubMed ID: 37231835
    [Abstract] [Full Text] [Related]

  • 32. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K, Kakuta H.
    Eur J Pharmacol; 2015 Nov 05; 766():129-34. PubMed ID: 26452517
    [Abstract] [Full Text] [Related]

  • 33. The influence of poly(allylamine hydrochloride) hydrogel crosslinking density on its thermal and phosphate binding properties.
    Elsiddig R, O'Reilly NJ, Hudson SP, Owens E, Hughes H, O'Grady D, McLoughlin P.
    Int J Pharm; 2022 Jun 10; 621():121806. PubMed ID: 35526696
    [Abstract] [Full Text] [Related]

  • 34. Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
    Rosenbaum DP, Holmes-Farley SR, Mandeville WH, Pitruzzello M, Goldberg DI.
    Nephrol Dial Transplant; 1997 May 10; 12(5):961-4. PubMed ID: 9175050
    [Abstract] [Full Text] [Related]

  • 35. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
    Fishbane S, Delmez J, Suki WN, Hariachar SK, Heaton J, Chasan-Taber S, Plone MA, Moe S.
    Am J Kidney Dis; 2010 Feb 10; 55(2):307-15. PubMed ID: 20042256
    [Abstract] [Full Text] [Related]

  • 36. Endotoxin-binding affinity of sevelamer hydrochloride.
    Perianayagam MC, Jaber BL.
    Am J Nephrol; 2008 Feb 10; 28(5):802-7. PubMed ID: 18506105
    [Abstract] [Full Text] [Related]

  • 37. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
    Sanai T, Tada H, Ono T, Fukumitsu T.
    Hemodial Int; 2015 Jan 10; 19(1):54-9. PubMed ID: 24980286
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA, Shepler BM.
    Pharmacotherapy; 2010 Jul 10; 30(7):741-8. PubMed ID: 20575637
    [Abstract] [Full Text] [Related]

  • 39. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK, Slatopolsky EA, Goldberg DI.
    Nephrol Dial Transplant; 1997 Aug 10; 12(8):1640-4. PubMed ID: 9269642
    [Abstract] [Full Text] [Related]

  • 40. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB.
    Semin Dial; 2007 Aug 10; 20(4):329-32. PubMed ID: 17635823
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.